Modulación Inmunológica Durante el Tratamiento con Palynziq® en Adultos (IMPALA)
Un estudio de fase 4 de modulación inmunitaria durante el tratamiento con Palynziq® en adultos con fenilcetonuria (PKU)
Study 165-401 is a Phase 4, open-label study designed to examine the concomitant use of methotrexate (MTX) to suppress immune responses to Palynziq and improve tolerability and efficacy in adults with PKU.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The overall objective of the study is to evaluate the ability of MTX, when co-administered with Palynziq, to suppress immune responses to Palynziq and thus improve the tolerability and efficacy of Palynziq in adults with phenylketonuria (PKU). Up to 12 participants will be enrolled into the study across 2 cohorts, with a target enrollment of 6 participants into each cohort:
- Cohort A: Individuals with uncontrolled blood phenylalanine (Phe) > 600 μmol/L on existing management who have never been treated with Palynziq (Palynziq naïve)
- Cohort B: Individuals who have uncontrolled blood Phe > 600 μmol/L after ≥ 24 consecutive weeks of treatment with Palynziq, are on a current dose of≥ 20mg/day, and are unable to further dose escalate (Palynziq experienced)
Palynziq will be initiated (Cohort A) or will continue (Cohort B) as indicated in the Palynziq United States Prescribing Information (USPI) and as prescribed by the participant's treating physician. The decision to initiate or continue Palynziq must be made independently of participation in this study. Palynziq and MTX will not be supplied by BioMarin as part of participation in this study.
All participants will be administered MTX at an oral dose of 15 mg/week concurrent with Palynziq:
- Cohort A participants will have a 4-week Screening Period, followed by a 4-week MTX Tolerability Period during which only MTX will be administered. If MTX is tolerated during the MTX Tolerability Period, the participant will then enter the 24-week Combination Treatment Period during which MTX + Palynziq will be administered concurrently.
- Cohort B participants will have a 4-week Screening Period. Participants will then have 24 weeks of concurrent MTX + Palynziq treatment (Combination Treatment Period): participants will be assessed for MTX tolerability during the first 4 weeks of MTX + Palynziq (MTX Tolerability Period) and then receive another 20 weeks of MTX + Palynziq.
After completion of Week 24 (Combination Treatment Period), MTX will be discontinued for both cohorts and Palynziq only will continue for another 24 weeks (to Week 49; Follow-up Period).
Participants will be assessed for safety and MTX tolerability. If a participant in either Cohort A or B is unable to tolerate MTX, the participant will be discontinued from MTX treatment. Participants who discontinue from MTX early should continue to complete the remaining study assessments until as long as such continued participation will not detrimentally affect the health, safety, and welfare of the participant per investigator determination
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Trial Specialist
- Número de teléfono: 1-800-983-4587
- Correo electrónico: medinfo@bmrn.com
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- Reclutamiento
- UCLA Dept. of Human Genetics
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- Children's Hospital Colorado
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33613
- Reclutamiento
- University Of South Florida Medical Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Reclutamiento
- Indiana University School of Medicine
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Reclutamiento
- University of Minnesota Medical School
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- Reclutamiento
- University of Rochester Medical Center (URMC)
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- Oregon Health & Science University (OHSU) - PARENT
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Aún no reclutando
- University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- UT Southwestern Medical Center
-
Contacto:
- Markey McNutt
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84108
- Aún no reclutando
- University of Utah Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- Children's Hospital of Wisconsin
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults between 18 and 65 years old
- Have a confirmed diagnosis of phenylketonuria (PKU)
- Are in generally good health based on medical evaluation
- Are willing and medically eligible to receive Palynziq and methotrexate (MTX) Cohort A: Have never taken Palynziq before and are willing to start it during the study Cohort B: Have blood > 600 μmol/L after taking Palynziq for at least 24 weeks, are on a daily dose of at least 20mg and unable to increase the dose further
- Agree to use required contraception if they or their partner could become pregnant
- Are willing to carry two epinephrine devices at all times during Palynziq treatment
Exclusion Criteria:
- Pregnant, breastfeeding, planning to become pregnant, planning to father a child, or not using effective birth control if applicable
- Have a known severe allergy or hypersensitivity reaction to methotrexate (MTX), Palynziq, or other PEG-containing medications
- Have a serious active infection or a history of severe or recurrent infections
- Have significant medical conditions that may affect safety or participation (such as serious heart, lung, liver, kidney, immune, neurological, psychiatric, or cancer-related conditions)
- Have a history of substance or alcohol abuse within the past 12 months
- Have had an organ transplant or are taking chronic immunosuppressive medications
- Are currently taking medications that are not allowed in the study, including other PKU treatments besides Palynziq
- Are using, or plan to use, injectable PEG-containing medications other than Palynziq during the study
- Have major surgery planned during the study participation period
- Are currently participating in another clinical study involving Palynziq
- In the opinion of the study doctor, are not a suitable candidate for the study or may have difficulty complying with study requirements
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Palynziq naïve
Individuals with uncontrolled blood phenylalanine (Phe) > 600 μmol/L on existing management who have never been treated with Palynziq. Participants will have a 4-week Screening Period, followed by a 4-week MTX Tolerability Period during which only MTX will be administered. If MTX is tolerated during the MTX Tolerability Period, the participant will then enter the 24-week Combination Treatment Period during which MTX + Palynziq will be administered concurrently. After completion of Week 24 (Combination Treatment Period), MTX will be discontinued for both cohorts and Palynziq only will continue for another 24 weeks (to Week 49). |
Pegvaliase (Palynziq) administered by subcutaneous injection. Dosing follows U.S. Prescribing Information and investigator judgement.
Otros nombres:
Oral methotrexate 15 mg administered once weekly during the Tolerability Period and the Combination Treatment Period.
Otros nombres:
|
|
Experimental: Palynziq experienced
Individuals who have uncontrolled blood Phe > 600 μmol/L after ≥ 24 consecutive weeks of treatment with Palynziq, are on a current dose of ≥ 20mg/day and are unable to further dose escalate (Palynziq experienced). Participants will have a 4-week Screening Period. Participants will then have 24 weeks of concurrent MTX + Palynziq treatment (Combination Treatment Period): participants will be assessed for MTX tolerability during the first 4 weeks of MTX + Palynziq (MTX Tolerability Period) and then receive another 20 weeks of MTX + Palynziq. After completion of Week 24 (Combination Treatment Period), MTX will be discontinued for both cohorts and Palynziq only will continue for another 24 weeks (to Week 49). |
Pegvaliase (Palynziq) administered by subcutaneous injection. Dosing follows U.S. Prescribing Information and investigator judgement.
Otros nombres:
Oral methotrexate 15 mg administered once weekly during the Tolerability Period and the Combination Treatment Period.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in blood Phe levels from baseline to Week 25 and Week 49
Periodo de tiempo: Baseline to Week 25 and Baseline to Week 49
|
To evaluate blood Phe response in adults with PKU co-administered Palynziq with MTX for 6 months |
Baseline to Week 25 and Baseline to Week 49
|
|
Anti-PEG IgG, IgM, anti-PAL IgG, IgM levels at Weeks 5, 9, 25, and 49
Periodo de tiempo: Baseline to Week 5, Week 9, Week 25, and Week 49
|
To evaluate the ability of MTX to modulate the immune response to Palynziq in adults with PKU |
Baseline to Week 5, Week 9, Week 25, and Week 49
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of TEAEs
Periodo de tiempo: Baseline through Week 49
|
To evaluate the safety of co-administration of Palynziq with MTX in adults with PKU. A TEAE is defined as any AE that newly appeared, increased in frequency, or worsened in severity following initiation of the study drugs (MTX or Palynziq) administration. Incidence of TEAEs will be defined as (number of TEAEs)/(total exposure time in person-years) *100 |
Baseline through Week 49
|
|
Trough Palynziq plasma PK
Periodo de tiempo: Baseline through Week 49
|
To characterize the PK of Palynziq during co-administration with MTX in adults with PKU |
Baseline through Week 49
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in IgG-C3d CIC, C3, C4 levels from baseline to Weeks 9, 25, and 49
Periodo de tiempo: Baseline to Weeks 9, 25, and 49
|
To evaluate formation of CIC and activation of complement pathway. Change from baseline to time t for each participant will be defined as (blood level at time t) - (blood level at baseline) |
Baseline to Weeks 9, 25, and 49
|
|
Percentage of participants in Cohort B that have escalated from dose at enrollment
Periodo de tiempo: Baseline to Week 24 and Week 48
|
To evaluate ability to dose escalate in Cohort B participants following co-administration of Palynziq with MTX |
Baseline to Week 24 and Week 48
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Medical Director, MD, BioMarin Pharmaceutical
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Metabolismo, errores congénitos
- Enfermedades Genéticas Congénitas
- Enfermedades metabólicas
- Enfermedades Cerebrales Metabólicas Congénitas
- Enfermedades Cerebrales Metabólicas
- Metabolismo de aminoácidos, errores congénitos
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Enfermedades Nutricionales y Metabólicas
- Fenilcetonurias
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Pterins
- Pteridinas
- Aminopterina
- Metotrexato
- Pegvaliase
Otros números de identificación del estudio
Otros números de identificación del estudio
- 165-401
- 2021-005058-27 (Número EudraCT)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .